Comparative Pharmacology
Head-to-head clinical analysis: GENTAFAIR versus GENTAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAFAIR versus GENTAK.
GENTAFAIR vs GENTAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
Gentamicin 3-5 mg/kg IV or IM once daily; alternatively, 1.5-2.5 mg/kg IV or IM every 8 hours.
None Documented
None Documented
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
2–3 hours in adults with normal renal function; prolonged to 24–60 hours in severe renal impairment (CrCl <10 mL/min).
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Renal excretion of unchanged drug accounts for >90% of elimination; <5% biliary/fecal.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic